PDS Biotechnology logo

PDSB - PDS Biotechnology News Story

$6.28 -0.1  -2.0%

Last Trade - 19/01/22

Sector
Healthcare
Size
Small Cap
Market Cap £134.1m
Enterprise Value £82.8m
Revenue £n/a
Position in Universe 4894th / 7398

BRIEF-PDS Biotechnology, Farmacore Jointly Prioritized Advancement Of PDS0203 To Human Clinical Trials

Tue 10th November, 2020 9:47pm
Nov 10 (Reuters) - PDS Biotechnology Corp  PDSB.O :
    * PDS BIOTECHNOLOGY - CO & FARMACORE HAVE JOINTLY
PRIORITIZED
ADVANCEMENT OF PDS0203 TO HUMAN CLINICAL TRIALS
    * PDS BIOTECHNOLOGY - FARMACORE IS IN DISCUSSIONS WITH
SPECIFIC
AGENCIES OF GOVERNMENT TO EXTEND PRECLINICAL FUNDING FOR PDS0203
    * PDS BIOTECHNOLOGY - HUMAN CLINICAL TRIAL OF PDS0203
ANTICIPATED
TO BEGIN DURING FIRST HALF OF 2021

Source text for Eikon:  ID:nGNX2x53rX 
Further company coverage:  PDSB.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.